Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11689500 | 0.92 | EPHX1 (0.48) | EPHX1NFE2L2MAOBFADS1KDM1A | |
| SCHEMBL270441 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL1199563 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL1103798 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL12914371 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL63809 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL3644410 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL1199046 | 0.84 | EPHX1 (0.52) | EPHX1MAOBPLAUKDM1AMAOA | |
| SCHEMBL11287657 | 0.81 | MDM2 (0.48) | EPHX1FADS1TSHR | |
| SCHEMBL6570141 | 0.81 | EPHX1 (0.50) | EPHX1MAOBPLAUKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110002978-B | Method for preparing phenylacetaldehyde and derivatives thereof by gas phase rearrangement method | 河南科技大学 | 2022-03-11 | — | — | CN | disclosed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | EPHX1 550/4885NFE2L2 1970/4885MAOB 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.